ストックスクリーナーアプリを入手
4.67
0.86%
0.04
アフターアワーズ：
4.73
0.06
+1.28%
前日終値:
$4.63
開ける：
$4.73
24時間の取引高:
79,148
Relative Volume:
2.09
時価総額：
$10.94M
収益：
$3.19M
当期純損益:
$-2.23M
株価収益率:
-3.7989
EPS:
-1.2293
ネットキャッシュフロー:
$-1.82M
1週間 パフォーマンス:
+17.34%
1か月 パフォーマンス:
+66.19%
6か月 パフォーマンス:
+92.98%
1年 パフォーマンス:
+51.84%
1日の値動き範囲:
$4.41
$4.9039
1週間の範囲:
$3.9535
$4.9392
52週間の値動き範囲:
$1.90
$13.93
Xenetic Biosciences Inc Stock (XBIO) Company Profile
名前
Xenetic Biosciences Inc
セクター
電話
781-778-7720
住所
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
4.67 | 7.94M | 3.19M | -2.23M | -1.82M | -1.2293 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-01-08 | 開始されました | Maxim Group | Buy |
Xenetic Biosciences Inc (XBIO) 最新ニュース
Xenetic Biosciences Inc. Warrants (XBIOW) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Xenetic Biosciences Inc. Warrants (XBIOW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Xenetic Biosciences Inc. Warrants (XBIOW) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Xenetic Biosciences, Inc. Revenue Breakdown – NASDAQ:XBIO - TradingView
XBIO Q2 2025 Earnings: Narrower-Than-Expected Loss of -$0.45 Beats Estimates by 31.07%Financial Health Score - vinanet.vn
Xenetic Biosciences Q2 royalty revenue rises on Takeda sublicense - TradingView
Xenetic Biosciences reports Q2 2026: $0.7M royalty revenue, $0.9M quarterly net loss - TradingView
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform - Yahoo Finance
Xenetic Biosciences: Q2 Earnings Snapshot - marketscreener.com
Xenetic partner receives Israeli approvals for lymphoma study - Stock Titan
Xenetic Biosciences, Inc. 2026: Revenue $660.6K, EPS ($0.41) — 10-Q Summary - tradingview.com
Xenetic Biosciences (XBIO) Rises 3.31% to $2.81, Approaching Key Resistance at $2.95TWAP Entry - dars.gov.et
XBIO Q2 2025 Earnings: Narrower Loss of $0.45 per Share Beats Estimates Despite No RevenueEarnings Surprise Stocks - vinanet.vn
Xenetic Biosciences Inc. (XBIO) Q2 2025 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline - dars.gov.et
Xenetic Biosciences Inc. (XBIO) Q2 2025 Earnings: EPS Beat Driven by Cost Discipline Amid Clinical-Stage OperationsReturn On Capital - vinanet.vn
Xenetic Biosciences Inc (XBIO) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
Xenetic Biosciences Inc (XBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xenetic Biosciences Inc (XBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XBIO|Xenetic Biosciences Inc|Price:2.640|Chg%:-0.085 - TradingKey
Xenetic Biosciences Inc (XBIO) Cash Flow - TradingKey
Xenetic Biosciences Inc (XBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Xenetic Biosciences Inc (XBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xenetic Biosciences Inc (XBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XBIO Q2 2025 Earnings: Narrower-Than-Expected Loss Drives Stock HigherFinal Results - dars.gov.et
Xenetic Biosciences (XBIO) Slides 1% as Shares Approach Key SupportTurnaround Stocks - vinanet.vn
Xenetic Biosciences (XBIO) Rises 3.58% as Biotech Stock Nears Key ResistanceSize Factor - dars.gov.et
Number of shareholders of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to book forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Enterprise value to revenue forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to earnings forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Enterprise value to EBITDA forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to sales forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Enterprise value to EBIT forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Xenetic Biosciences (XBIO) Surges 6.14% as Stock Tests Key Resistance at $3.09Large Cap Trends - dars.gov.et
XBIOXenetic Biosciences Inc Latest SEC Filings - Finviz
Xenetic Biosciences, Inc. Actuals & Estimates (NASDAQ:XBIO) - TradingView
Xenetic Biosciences Inc (XBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xenetic Biosciences Inc (XBIO) Institutional Confidence - TradingKey
Xenetic Biosciences Inc (XBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xenetic Biosciences (XBIO) Gains 6.7% – Bullish Breakout Within Tight RangeBreakout Stock Alerts - newsline.com
Xenetic Biosciences Inc. (XBIO) Q2 2025 Earnings: Narrowed Loss Beats Expectations, Pipeline Progress KeyRevenue Surprise History - dars.gov.et
XBIO Q2 2025 Earnings: EPS Surpasses Estimates Despite No RevenueLong-Term Guidance - dars.gov.et
XBIO Q2 2025 Earnings: Narrower Loss Beats Estimates, Yet Stock Slips on No Revenue ProgressAnalyst Coverage Count - dars.gov.et
Xenetic Biosciences (XBIO) Secures Approval for Clinical Study i - GuruFocus
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma - ACCESS Newswire
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates - MSN
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival - BioSpace
Xenetic presents preclinical data on DNase I with CAR-T therapy - Investing.com Nigeria
Xenetic (XBIO) Reveals Promising Preclinical Results for CAR-T Therapy - GuruFocus
Xenetic presents preclinical data on DNase I with CAR-T therapy By Investing.com - Investing.com South Africa
Xenetic Biosciences Inc (XBIO) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):